# Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

> **NCT01402531** · PHASE2 · COMPLETED · sponsor: **University of California, San Diego** · enrollment: 10 (actual)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia (HHT)

## Interventions

- **DRUG:** Submucosal Bevacizumab

## Key facts

- **NCT ID:** NCT01402531
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-22
- **Primary completion:** 2013-07-27
- **Final completion:** 2013-07-27
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01402531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01402531, "Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01402531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*